Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m(2) Journal Article

  


Authors: Kris, M. G.; Clark, R. A.; Tyson, L. B.; Hahne, W. F.; Pisters, K. M. W.; Gralla, R. J.
Article Title: Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m(2)
Abstract: Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95% confidence interval: 9-49%), and 45% had two or fewer emetic episodes (95% confidence interval: 23-69%). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42% no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25% of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.
Keywords: adult; cancer chemotherapy; clinical article; aged; cisplatin; diarrhea; drug efficacy; cancer patient; phase 2 clinical trial; etoposide; vomiting; sedation; vinblastine; serotonin antagonist; ondansetron; antiemetic agent; headache; mitomycin; intravenous drug administration; cancer; human; male; female; article
Journal Title: American Journal of Clinical Oncology
Volume: 16
Issue: 1
ISSN: 0277-3732
Publisher: Lippincott Williams & Wilkins  
Date Published: 1993-02-01
Start Page: 77
End Page: 80
Language: English
DOI: 10.1097/00000421-199302000-00019
PUBMED: 8424410
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027402802&doi=10.1097%2f00000421-199302000-00019&partnerID=40&md5=81ea9ba4f05b1815af6b9174ad43d13c
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Mark Kris
    869 Kris
  2. Leslie Tyson
    70 Tyson
  3. Katherine M. W. Pisters
    27 Pisters
  4. Richard J. Gralla
    69 Gralla
  5. Rebecca Clark
    21 Clark
Related MSK Work